The mutational activation of oncogenes drives cancer development and progression. Classic oncogenes, such as MYC and RAS, are active across many different cancer types. In contrast, "lineage-survival" oncogenes represent a distinct and emerging class typically comprising transcriptional regulators of a specific cell lineage that, when deregulated, support the proliferation and survival of cancers derived from that lineage. Here, in a large collection of colorectal cancer cell lines and tumors, we identify recurrent amplification of chromosome 13, an alteration highly restricted to colorectal-derived cancers. A minimal region of amplification on 13q12.2 pinpoints caudal type homeobox transcription factor 2 (CDX2), a regulator of normal intestinal lineage development and differentiation, as a target of the amplification. In contrast to its described role as a colorectal tumor suppressor, CDX2 when amplified is required for the proliferation and survival of colorectal cancer cells. Further, transcriptional profiling, binding-site analysis, and functional studies link CDX2 to Wnt/β-catenin signaling, itself a key oncogenic pathway in colorectal cancer. These data characterize CDX2 as a lineage-survival oncogene deregulated in colorectal cancer. Our findings challenge a prevailing view that CDX2 is a tumor suppressor in colorectal cancer and uncover an additional piece in the multistep model of colorectal tumorigenesis.
C olorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women, with ∼141,000 new cases and ∼49,000 deaths per year in the United States (1) . The classical model of colorectal tumorigenesis proposed by Vogelstein et al. (2) more than 20 y ago describes the most common mutations found in CRC. In cancers with the more common chromosomal instability (CIN), operationally defined by the presence of multiple chromosomal gains, losses, and translocations that alter expression of cancer genes (3, 4) , the sequence of events from early adenoma formation to carcinoma includes loss of adenomatous polyposis coli (APC), leading to transcriptional activation of Wnt target genes, activating mutations in the small GTPase KRAS, resulting in constitutive Ras-signaling, mutations in TP53, and loss of the long arm of chromosome 18 (i.e., DCC, SMAD4), which is the most common cytogenetic abnormality in CRC and is associated with an unfavorable outcome (5) . In contrast, tumorigenesis in CRCs with microsatellite instability (MSI), defined by defects in DNA mismatch repair, follows a pathway distinct from but analogous to that typified by CIN tumors. The initial step involves alterations in Wnt signaling (6) , followed by activating mutations in BRAF (instead of KRAS) (7) . Mismatch repair deficiency further disrupts cancer genes harboring coding-sequence microsatellite tracts, such as TGF-β receptor 2 (TGFBR2), insulin-like growth factor 2 receptor (IGF2R), and the apoptosis regulator BAX.
More recently, large-scale exome sequencing efforts have added a layer of complexity to the genomic landscape of colorectal cancers (8, 9) , identifying additional mutations and highlighting the considerable genetic heterogeneity among patient tumors. Additionally, several studies have surveyed DNA copy number alterations (CNAs) in CRC, establishing that CIN tumors harbor numerous broad gains and losses, often affecting whole chromosome arms; common alterations include gain of chromosome arms 7p (EGFR), 8q (MYC), 11p, 13q, and 20q and loss of 1p, 4q, 5q (APC), 8p, 17p (TP53), and 18q (DCC, SMAD4) (10) (11) (12) (13) . Because of the large number of genes spanned by most of these alterations, pinpointing new driver cancer genes has proven challenging. A promising strategy to hone in on such drivers is to compare genomic data across multiple tumor types, where lineage-specific alterations might point to cancer genes playing a critical role in the development of cancers arising from a specific cell lineage (14) .
Here, we carried out an integrative genomic analysis of colorectal cancer, surveying a collection of 29 colorectal cancer cell lines and publicly available data on 226 primary colorectal tumors for somatic DNA CNAs. By comparison with the genomic profiles of thousands of samples from diverse tumor types, we unveiled a region of amplification highly specific to colorectal-derived tumors. We identified caudal type homeobox transcription factor 2 (CDX2), a master regulator of intestinal cell survival and differentiation, as a target gene of this amplification. We performed functional studies and genome-wide location and transcriptome analysis to uncover a context-dependent role for CDX2 in Wnt/ β-catenin signaling and CRC tumorigenesis. These data show that for a subset of colorectal-derived tumors, cell survival and proliferation are dependent on the abnormal amplification and overexpression of CDX2. Further, they characterize CDX2 as a lineage-survival oncogene in colorectal cancer and provide additional insight into colorectal pathobiology.
Results
Recurrent 13q12 Amplification in Colorectal Cancer Targets CDX2. We profiled somatic DNA CNAs in 29 colorectal cancer cell lines and reanalyzed data from 226 primary colorectal tumors (15, 16) , using Genomic Identification of Significant Targets in Cancer (GISTIC) (17) to identify recurrent amplifications or deletions and peak regions likely to harbor driver cancer genes. Consistent with previous studies (10-13), we identified numerous somatic CNAs including gain of chromosome arms 1q, 7p (EGFR), 8q (MYC), 13q, and 20q and loss of 1p, 4q, 5q (APC), 8p, 17p (TP53), and 18q (DCC, SMAD4) ( Fig. 1A and SI Appendix, Fig. S1 ).
After amplification of 8q24 (encompassing the colorectal oncogene MYC), the most significant recurrent alteration was amplification on the long arm of chromosome 13, observed in 11 of 29 (38%) colorectal cancer cell lines and 121 of 226 (54%) primary tumors. To validate this finding, we performed FISH on a tissue microarray (TMA) of 76 evaluable primary colorectal tumors (using a commercially validated FISH probe mapping to 13q14) and confirmed increased copy number of 13q in 32 of 76 (42%) cases (SI Appendix, Fig. S2A and Table S1 ). Although most amplification events were broad (i.e., more than half the length of the chromosome arm), a number of focal amplifications helped define three GISTIC-identified peaks on 13q (Table 1) . The most significant peak maps to chromosome segment 13q12.2 (Fig. 1B) , and reprofiling the sample harboring the most focal region of amplification (CRC cell line COLO320) using the high-resolution Affymetrix SNP 6.0 array revealed a 168-kb high-level amplification spanning just two genes, pancreatic-duodenal homeobox transcription factor 1 (PDX1) and CDX2 (Fig. 1C) ; among primary tumors, the region of highest amplification includes only CDX2. This amplification resides adjacent to a recently described focus of copy number gain in colorectal cancers at 13q12.13 containing candidate oncogene CDK8 (15). Although CDX2 and CDK8 often COLO320  COLO205  NCI-H508  SW948  HT29  SW1116  SKCO1  SW480  LS411  COLO741  CACO2  SW403  LS180  LS174T  SNUC2B  NCI-H747   DLD1  LIM1215  HCT15  HCT116  SW48  RKO  LOVO  LIM2412  SW1417   T84  HCA7  SW837 . Shown are short and long exposures using an anti-CDX2 antibody; GAPDH serves as a loading control. Relative CDX2 expression levels are indicated, normalized to GAPDH and referenced to SW620 (set to 1). Note: SW480 and SW620 are matched primary and metastasis-derived lines from the same patient; the absence of 13q gain in SW620 and the relatively low CDX2 expression in both lines suggest that 13q gain is not a driving event for this tumor.
were coamplified, in our analysis of 255 colorectal cancer samples (including the ones used to nominate CDK8) (15, 16), we found six primary tumors and two cell lines that exclude CDK8 from the peak region of 13q12.2 amplification; in contrast, only one cell line harbors an amplification excluding CDX2 (Fig. 1B and SI Appendix, Fig. S3 ). This result suggests that CDX2 is more often targeted for amplification, and thus CDK8 may not be the primary target of 13q12.2 amplification in colorectal cancers. Additional 13q peaks of amplification include transcriptional activator KLF5 at 13q22.1 and insulin-signaling gene IRS2 at 13q34 (Table 1 and SI Appendix, Fig. S1 and Table S2 ); a colorectal cancer susceptibility variant resides in the latter (18) . PDX1 and CDX2, along with GSX1 (outside the amplification), form the ParaHox gene cluster at 13q12.2. PDX1 is a tissuespecific transcriptional activator in the early developing and adult pancreas, and defects of PDX1 are a cause of pancreatic agenesis (19, 20) . CDX2, a master transcriptional regulator of intestinal cell fate and survival, has been used as a marker to indicate colorectal differentiation in adenocarcinomas of unknown origin. Given its lineage-specific function, we examined a compendium of genomic profiles of 3,131 samples from 26 distinct histological types (21) and found that CDX2 is amplified significantly only in colorectal-derived tumors (q < 10 ) (SI Appendix, Table S3 ). Further, among 1,911 tumor specimens across 16 distinct tumor types (22) , CDX2 expression also is significantly associated with colorectal-derived tumors (P < 10 −153 ) (SI Appendix, Fig. S4 ). Interestingly, CDX2 has been characterized as a colorectal tumor suppressor in mouse models (23) (24) (25) . However, CDX2 sequence mutations are exceedingly rare-only 3 of 224 previously sequenced colorectal cancer cell lines and tumors harbor a mutation (0.9% mutant allele frequency), and all of those mutations occur in repeat sites of cancers with microsatellite instability (9, (26) (27) (28) (29) -and although it harbors tumor-suppressor gene RB1, loss of chromosome 13 is rarely observed in colorectal cancers (SI Appendix, Figs. S1 and S3). Among the 29 cell lines surveyed in this study, one MSI + cell line (RKO) harbors a previously identified heterozygous CDX2 mutation; we uncovered one additional heterozygous frameshift mutation (c.1090delG) in a repeat sequence in MSI + cell line LIM2412. The frameshift is predicted to replace the eight terminal amino acids of CDX2 with one alternate amino acid (followed by a stop codon encoded by the shifted reading frame); the functional significance (if any) of this mutation is unknown. Additionally, we analyzed the CpG island spanning the CDX2 promoter and transcription start site in 11 representative cell lines and found the majority of CpG sites in all cell lines to be unmethylated (SI Appendix, Fig. S5 ). These observations suggest that the infrequent CDX2 mutations are likely secondary to genomic instability and argue against an important role for CDX2 as a colorectal tumor-suppressor gene.
Colorectal Cancer Cells with 13q12 Amplification Exhibit CDX2
Dependency. To determine the impact of 13q amplification on CDX2 expression, we performed immunohistochemistry on the same colorectal cancer specimens analyzed by FISH and found nuclear CDX2 staining in 51 of 76 (67%) cases, with a correlation between 13q copy number and CDX2 protein expression (ρ = 0.37, P = 0.001; Spearman correlation) (SI Appendix, Fig. S2 A and B and Table S1 ). We next analyzed the panel of 11 colorectal cancer cell lines and found that cell lines with 13q12.2 gain or amplification (validated by quantitative PCR (SI Appendix, Fig.  S2C ) generally display elevated CDX2 transcript (P = 0.04, Mann-Whitney u test; SI Appendix, Fig. S2D ) and protein levels (P = 0.07; Fig. 1D ) as compared with cell lines without the amplification or as compared with normal colonic epithelium (i.e., isolated colonic mucosa uninvolved by cancer) (transcript levels P = 0.09, protein levels P = 0.02; SI Appendix, Fig. S2 D and E). A notable exception was the disomic cell line DLD1, which showed CDX2 expression levels comparable to those in amplified cell lines. In contrast, we found no significant difference in PDX1 transcript or protein levels in colorectal cancer cell lines with and without 13q12.2 amplification or as compared with normal colonic epithelium (SI Appendix, Fig. S6 A and B), indicating that PDX1 is likely a passenger of 13q12.2 amplification.
Within the cohort of 76 colorectal cancer cases evaluated for 13q gain (by FISH) and CDX2 expression (by immunohistochemistry, IHC), 13q gain was associated with advanced pathologic stage (P = 0.039; Fisher's exact test) but not with tumor grade or overall survival (SI Appendix, Table S4 ). CDX2 expression showed a similar although nonsignificant trend (SI Appendix, Table S4 ). Within the collection of colorectal cancer cell lines, CDX2 gain/overexpression did not correlate significantly with other commonly occurring colorectal cancer gene mutations, including TP53, KRAS, BRAF, APC, CTNNB1, PIK3CA, and SMAD4 (SI Appendix, Table S5 ).
We next evaluated the dependence on CDX2 expression of colorectal cancer cell lines bearing 13q12.2 amplification. RNAi by five independent shRNA and four independent siRNA in COLO320 cells revealed a profound sensitivity to reduced CDX2 expression ( Fig. 2A and SI Appendix, Fig. S7 A and B). To characterize this dependency in more detail, we suppressed CDX2 expression in six cell lines, three with amplification of 13q12.2 (COLO320, SW948, and SKCO1) and three without (DLD1, NCI-H747, and SW837), using CDX2-or control GFP-targeting shRNAs (shCDX2-1, shCDX2-3, and shGFP) (Fig. 2B ). Knockdown of CDX2 inhibited proliferation in all three cell lines with 13q12.2 amplification but not in any cell line without the amplification (Fig. 2C) . Notably, proliferation was not reduced in DLD1 cells expressing high levels of CDX2, suggesting an amplificationassociated, context-specific dependency on CDX2 not explainable by expression levels alone. To dissect the observed effect further, we measured the immediate effect of CDX2 suppression on cellcycle progression and apoptosis and found that in COLO320 cells both of two CDX2-directed siRNAs inhibited cell-cycle progression and induced apoptosis (SI Appendix, Fig. S7 C and D) . These observations suggest that colorectal cancers with 13q12.2 amplification depend on deregulated CDX2 expression.
We also tested tumor cell dependency on CDK8 expression in the same panel of colorectal cancer cell lines. By CDK8-directed siRNA knockdown, suppression of CDK8 expression in our hands had no significant effect on cell viability in cell lines with or without 13q12.2 amplifications spanning CDK8 (SI Appendix, Fig. S8 ). Together with the observation of multiple 13q12.2 amplifications excluding CDK8, and only one amplification spanning CDK8 that excludes CDX2 (in cell line SW403), these data strongly suggest that CDX2 (and not CDK8) is the important target gene of 13q12.2 amplification. See also SI Appendix, Fig. S3 and Table S2 . *GISTIC-defined significant peaks of recurrent amplification. Similarly, we determined that knockdown of PDX1 does not affect cell viability in COLO320 cells, in which PDX1 and neighboring CDX2 are highly coamplified (SI Appendix, Fig. S6 C and D) .
We next examined the effect of CDX2 amplification on anchorageindependent growth. CDX2-directed shRNAs markedly diminished soft agar colony formation in CDX2-amplified COLO320, SW948, and SKCO1 cells but had no effect in DLD1 and SW837 control cells lacking the amplification (Fig. 2D) . NCI-H747 was not tested because in our hands this cell line failed to form colonies in soft agar. Because of the noted effect on proliferation, we sought to determine whether the observed reduction in colony formation upon CDX2 suppression represented a distinct phenotype or simply reflected an attenuated capacity for cell proliferation. By comparing colony formation in soft agar with that on tissue-culture plastic, we noted that knockdown of CDX2 represses anchorage-independent growth beyond its inhibitory effect on proliferation (SI Appendix, Fig. S7E ). In other phenotypes assayed, suppression of CDX2 did not affect cell migration or invasion consistently, irrespective of 13q12.2 amplification status (SI Appendix, Fig. S9 ). Finally, in contrast to the necessity of CDX2 for anchorage-independent growth, heterologous expression of CDX2 was not sufficient to transform immortalized rodent fibroblasts (NIH 3T3 cells) (SI Appendix, Fig. S7H ).
To confirm that the phenotypes observed using CDX2-directed shRNAs were caused specifically by CDX2 suppression, we attempted to rescue this phenotype by ectopic expression of CDX2. We coinfected COLO320 cells with shCDX2-1, which targets the 3′ UTR of CDX2 transcripts, and a CDX2 cDNA lacking the endogenous 3′ UTR. Forced expression of CDX2 successfully restored CDX2 protein levels and rescued both cell proliferation and colony formation to wild-type levels ( Fig. 2E and SI Appendix, Fig. S7 F and G) . These data demonstrate that the effects of our shRNA knockdowns are not caused by off-target RNAi and are attributable specifically to CDX2 suppression.
When Amplified, CDX2 Promotes Wnt/β-Catenin Signaling. We next sought to identify genes that might be under the regulatory control of CDX2 in the context of its aberrant amplification and oncogenic phenotype. We performed gene-expression profiling of COLO320 cells after siRNA-mediated CDX2 knockdown to identify genes that correlate with decreased CDX2 transcript levels (SI Appendix, Table  S6 ). Using gene set enrichment analysis (30), we found that the 185 genes most correlated with CDX2 expression levels (SI Appendix, Supplemental Materials and Methods) were involved in Wnt/β-catenin signaling (n = 9; P = 10 (Fig. 3A) . To determine the relevance of the cell line CDX2-knockdown signature to actual colorectal tumor samples, we investigated the signature genes in publicly available microarray expression datasets. Indeed, the genes correlating with CDX2 expression levels in COLO320 showed enrichment (significant or strong trend) among the top genes correlated with CDX2 expression in tumors (SI Appendix, Table S7 ).
Inspection of the enriched Wnt-signaling gene set (Fig. 3B ) revealed genes associated with canonical Wnt/β-catenin signaling (FZD8, CSNK2A1, FBXW11) as well as with the noncanonical planar cell polarity (RAC2) and Wnt/calcium (PLCB3, CAMK2D, PRICKLE2) pathways. Also included, WNT5A encodes a promiscuous noncanonical Wnt ligand that can either inhibit or stimulate β-catenin activity depending on the constellation of Wnt receptors (31) . Notably, the top-ranked gene, FZD8, encodes a Wnt receptor recently found to be overexpressed in lung cancer where it promotes cell proliferation and Wnt/β-catenin signaling (32) . The second-ranked gene, CSNK2A1, has been found to be essential for Wnt/β-catenin signaling (33) . Thus, the microarray data provide a strong rationale for further investigating a link between CDX2 and canonical Wnt signaling.
To complement our expression analysis and to identify direct transcriptional targets, we also performed ChIP followed by massively parallel sequencing (ChIP-seq) of CDX2 in COLO320 cells, uncovering 14,631 high-confidence binding peaks (>30-fold enrichment over input) across the genome. As one indicator that we identified occupancy of functional elements, we observed strong sequence conservation across multiple vertebrate species peaking at the center of our CDX2-binding regions (Fig. 3C) . Further, de novo motif scanning recovered an AT-rich motif highly similar to a CDX2-binding motif previously defined in vitro by proteinbinding microarrays (Fig. 3D) (34) . Finally, we identified a strong binding peak in the proximal promoter region of the intestinespecific sucrase-isomaltase gene, a well-characterized CDX2 transcriptional target (Fig. 3E) (35-37) .
Integrating ChIP-seq data with our CDX2 gene-expression signature revealed that 56 of the 185 differentially expressed genes had nearby CDX2 binding peaks (P = 0.006; hypergeometric test), including three of the Wnt-signaling genes (CSNK2A1, WNT5A, and CAMK2D) and one known CDX2 target gene, liver-intestine cadherin 17 (CDH17) (Fig. 3E and SI Appendix, Table S8 ) (38) . Additionally, we identified CDX2-binding peaks within and near Wnt/β-catenin effector genes LEF1 and TCF4 (Fig. 3E) . Taken together, these observations further implicate CDX2 as a positive regulator of Wnt/β-catenin signaling.
Buttressing this hypothesis, we analyzed a 100-bp window around our CDX2-binding peaks, where sequence conservation was highest, for enrichment of other transcription factor motifs in the TRANSFAC database (39); strikingly, the T-cell factor/lymphoid enhancer factor (TCF/LEF) consensus binding motif was significantly enriched (P < 10
; Fig. 3F ). This finding suggests that CDX2 might cooperate with TCF/LEF proteins to promote β-catenin transcriptional activity in COLO320, concordant with a recent report of CDX2 and TCF4 co-occupancy in Caco2 colorectal cancer cells (40) . As expected, the CDX consensus motif also was significantly enriched (P < 10
), as were motifs of other transcription factors known to interact with CDX2 to induce intestine-specific gene expression, such as GATA and HNF1 (Fig. 3F and SI Appendix, Table S10 ) (41, 42) .
To test directly whether CDX2 promotes β-catenin transcriptional activity, we transfected β-catenin/TCF-luciferase and mutant control-luciferase reporter constructs ("TOPflash" and "FOPflash," respectively) into 13q12.2-amplified and nonamplified cells stably expressing CDX2-directed or control shRNAs. Remarkably, CDX2 suppression significantly reduced (42-66% decrease) the TOPflash/ FOPflash ratio in COLO320 and SKCO1 cells (Fig. 4A) , suggesting that in the context of 13q12.2 amplification CDX2 promotes β-catenin/TCF-dependent transcriptional activity, a finding consistent with our expression array and ChIP-seq results. In contrast, CDX2 knockdown increased the TOPflash/FOPflash ratio in DLD1 and SW837 cells (although the basal ratio also was ∼40-400-fold lower than in COLO320 cells) (Fig. 4B) , suggesting that in a nonamplified context CDX2 actually inhibits β-catenin activity [concordant with recently reported findings for DLD1 (43)]. Consistent with our data linking CDX2 amplification/overexpression to β-catenin activity, we noted a significant correlation between levels of CDX2 and nuclear (active) β-catenin by IHC staining of TMA specimens (ρ = 0.48, P < 0.001; Spearman correlation) (Fig. 4C and SI Appendix, Fig. S10 and Table S1 ).
Discussion
We report here that CDX2 is an amplified oncogene in colorectal cancer. When amplified and overexpressed, colorectal cancers demonstrate a marked dependency on CDX2 levels for continued growth and survival. We further uncover a connection between CDX2 and Wnt/β-catenin signaling, possibly providing a unifying mechanism for the CDX2 contribution to colorectal tumorigenesis.
Collectively, CDX2 is gained/amplified in 52% of samples, but in the majority of cases a broad chromosomal event results in coamplification of CDX2 and CDK8. Although focal amplification generally is rare among known oncogenes and thus is not to be expected (21, 44), we were able to identify six primary tumors and two cell lines in which the peak region of amplification coincides with CDX2 and excludes CDK8. Conversely, only one cell line (SW403) and no primary tumor harbors an amplification that spans CDK8 but does not include CDX2. This genetic evidence, illustrated by the GISTIC amplification peak residing squarely over CDX2, points to CDX2 as the more likely target gene. Further, our side-by-side comparison of tumor cell dependency on CDK8 expression in the same panel of cell lines used to explore CDX2 demonstrates that suppression of CDK8 expression has no effect on cell viability in cell lines with or without amplification. In comparison with the study by Firestein et al. (15) , because the cell lines used were overlapping but ultimately different (DLD1 and SW837 were common to both studies, and CDK8 knockdown led to reduced viability in their hands but not in ours), we cannot overstate our own conclusions. We also can only speculate as to why Firestein et al. did not identify CDX2; this disparity may reflect the cell lines used (much of their initial work was done with nonamplified lines DLD1 and HCT116) and/or their apparent reliance on a single shRNA hairpin targeting CDX2. Nevertheless, we believe the genetic evidence, along with our experimental results, strongly supports a role for CDX2 (and not CDK8) as the primary driver of 13q12 amplification. We also note that amplicons often harbor multiple driver genes and that CDX2 may not be the only driver on chromosome 13 (indeed, two additional GISTIC peaks elsewhere on chromosome 13 were identified in our analysis). Last, The Cancer Genome Atlas Network also recently reported a 13q12 amplicon in colorectal cancers; the amplicon spanned 13 genes (including CDX2 but not CDK8), and, like our study, was associated with advanced stage (45) .
Our findings stand in contrast to mouse modeling that implicates Cdx2 as a tumor suppressor (23) (24) (25) [e.g., models in which Apc
Cdx2
+/− compound mutant mice develop increased colonic polyps (24)]. We and others also have found that CDX2 is mutated in rare cases of human colorectal cancer (4 of 230 cases surveyed to date). However, all the mutations occur within simple repeat sequences in MSI + cancers and thus, we believe, represent passenger mutations attributable to the 25-fold higher mutation rate of MSI + tumors (46) . The mouse modeling shows CDX2 has a capacity to suppress tumor growth in certain contexts, but our findings draw into question how faithfully current mouse models represent CDX2-associated human colorectal cancer (e.g., it is well known that APC min mice develop intestinal but not colorectal tumors). Although CDX2 might have dual roles as an oncogene and tumor suppressor (47), our genetic and functional data in human colorectal cancer overwhelmingly support a mainly oncogenic role. Future studies should clarify how well current mouse models reflect CDX2-driven human colorectal cancer and the extent to which human CDX2 also might function as a colonic tumor suppressor in some contexts.
CDX2 plays a critical role in gut formation and anteriorposterior patterning (48) , where its disruption leads to an anterior homeotic shift of both the axial skeleton and intestinal mucosa (23, 49) . In the adult colon, CDX2 plays an essential role in regulating survival and differentiation of intestinal epithelial cells as they traverse the colonic crypt-villus axis (50) . CDX2 overexpression also is involved in driving intestinal metaplasia in the stomach, a precursor lesion to intestinal-type gastric carcinoma (51, 52) , and appears to be a transforming event in acute myelogenous leukemia (53) . The master regulatory role of CDX2 in cell-survival mechanisms of the developing intestinal tract is congruent with the hypothesis that CDX2 may be a "lineage-survival" oncogene (14) . In this context, CDX2-amplified colorectal tumors may co-opt lineage-specific survival mechanisms embedded in intestinal stem/progenitor cells, reminiscent of AR amplification in prostate cancer (54) , MITF amplification in melanoma (55) , and TITF1 or SOX2 amplification in adenocarcinoma or squamous cell carcinoma of the lung (44, (56) (57) (58) , respectively. The highly lineage-restricted pattern of CDX2 amplification and expression we found across thousands of samples from diverse tumor types supports this hypothesis and suggests that CDX2 invokes lineage-dependent mechanisms to orchestrate an oncogenic phenotype. These data characterize CDX2 as a lineage-survival oncogene in colorectal cancer. Despite its amplification and dependency for cell proliferation and survival (hallmarks of oncogenes), we found that CDX2 alone does not transform immortalized rodent fibroblasts. However, this finding is consistent with a contextual role in tumorigenesis, the sine qua non of lineage-survival oncogenes. Indeed, to transform immortalized cells, MITF requires BRAF (55), SOX2 requires FOXE1 or FGFR2 (44), and TITF1 requires NKX2-8 or PAX9 (56) . An important focus of future studies will be to elucidate the genetic context in which CDX2 transforms cells.
Finally, we implicate Wnt/β-catenin signaling as a possible mechanism by which CDX2 contributes to colorectal tumorigenesis. Multiple lines of evidence support a connection between CDX2 and the canonical Wnt/β-catenin pathway: (i) CDX2 knockdown reduces expression of select canonical Wnt pathway genes; (ii) CDX2 binds genomic sites nearby select canonical Wnt pathway genes; (iii) CDX2 binds adjacent to TCF/LEF motifs genome-wide; (iv) CDX2 knockdown (in amplified cell lines) inhibits β-catenin/TCF reporter activity; and (v) CDX2 expression in colorectal tumors significantly correlates with nuclear β-catenin levels. Nonetheless, the detailed mechanism(s) by which CDX2 affects β-catenin activity and their relative importance remain to be clarified. Furthermore, because it is likely that Wnt/β-catenin is not the sole mediator of CDX2 oncogenic activity, future studies should explore other possible mediators, including noncanonical Wnt pathways, HOX genes, phosphatidylinositol signaling, and others.
Wnt/β-catenin signaling plays an integral role in the development of the colonic epithelium and represents a key pathway altered during colorectal tumorigenesis (59) . More than 90% of patients are purported to have alterations that affect the Wnt/β-catenin pathway (60) . Among our cell line collection, nearly all MSI − lines harbor the APC mutation, and nearly all MSI + cell lines harbor mutation in APC or β-catenin. Nonetheless, the high frequency of APC/β-catenin mutations does not preclude the importance of CDX2 amplification and involvement in the Wnt pathway. In fact, despite the near ubiquity of APC mutations, less than half of colorectal cancers show positive nuclear β-catenin staining by IHC [42% in our study and 40% in a previous report (61) ]. This result implies that more than one upstream mutation may be necessary to activate nuclear β-catenin signaling sufficiently. Our data are consistent with CDX2 amplification possibly functioning in this role and warrant further investigation of the relationship between CDX2 and Wnt/β-catenin signaling. Additional work to characterize the genes or pathway dependencies invoked by CDX2-driven tumors, perhaps through synthetic lethal screening, may point to new selective vulnerabilities in colorectal cancers harboring 13q12.2 amplifications and should be of potential clinical value.
Materials and Methods
See SI Appendix, Supplemental Materials and Methods for detailed discussion of experimental procedures.
Colorectal Cancer Cell Lines. Colorectal cancer cell lines were obtained from the American Type Culture Collection or the European Collection of Cell Cultures, unless otherwise specified (SI Appendix, Supplemental Materials and Methods). All cell lines were grown in RPMI-1640 with 10% (vol/vol) FBS.
Array-Based Comparative Genomic Hybridization. Array-based comparative genomic hybridization (aCGH) was done using cDNA microarrays representing 22,488 mapped human genes, according to previously published protocols (62, 63) , with map positions for arrayed cDNAs assigned using the National Center for Biotechnology Information genome assembly (Build 36.1). Copy number data were segmented using Circular Binary Segmentation (CBS) (64) , and statistically significant recurrent alterations were identified using GISTIC (17) . COLO320 also was profiled using an Affymetrix SNP 6.0 array. For primary colorectal tumors, DNA copy number data were obtained from 123 tumors profiled on Affymetrix 250K Mapping SNP arrays (15) and from 98 tumors profiled on Agilent 244K oligonucleotide arrays (16) . SNP array data were processed using GenePattern 2.0 (65), and copy number estimates were obtained using the SNP analysis module. SNP array and Agilent array copy number data were segmented using CBS and were analyzed using GISTIC. All genomic coordinates were mapped to the hg18 reference genome build. DNA amplifications and deletions were defined by CBS segments with mean log 2 ratios greater than 0.1 and less than −0.1, respectively.
Gene-Expression Profiling. To derive a CDX2 gene-expression signature, COLO320 cells were transfected with either of two CDX2-targeting siRNAs (siCDX2-1 or siCDX2-3) or a nontargeting control (NTC) siRNA. Cells were harvested 24 h later (coinciding with the time of maximal CDX2 protein knockdown), and RNA from siCDX2 and NTC was cohybridized to Agilent Whole Human Genome 44K geneexpression arrays. Expression data were normalized, and the intersection of the top 500 genes down-regulated upon CDX2 knockdown by each of the two CDX2-targeting siRNA constructs, compared with NTC, comprised our CDX2 gene-expression signature (185 genes). Enrichment for functionally related genes was evaluated by overlapping this signature with curated pathway gene sets from the Molecular Signatures Database (30) , and enrichment was calculated using the hypergeometric distribution.
ChIP-seq. ChIP was performed using two independent antibodies against human CDX2. ChIP and input DNA were sequenced using a Genome Analyzer IIx (Illumina). Raw sequence image data were analyzed using the Illumina analysis pipeline and mapped to the unmasked human genome (NCBI36, hg18) using ELAND (Illumina). Mapped sequences were analyzed for enriched binding peaks using QuEST (66) . The SeqPos program was used for de novo motif scanning of CDX2-binding regions and to identify enrichment of transcription factor-binding motifs. To integrate ChIP-seq-binding peaks with gene-expression data, we assigned each ChIP-seq peak to the nearest annotated gene.
FISH and IHC.
A TMA was constructed using archived formalin-fixed, paraffinembedded colon tissue specimens obtained with Institutional Review Board approval from the Santa Clara Valley Medical Center (San Jose, CA). The TMA contained duplicate 0.6-mm cores representing 76 evaluable colorectal adenocarcinomas. A set of overlapping, SpectrumOrange-labeled clones mapping to 13q14 (LSI13; Vysis) was cohybridized with a SpectrumGreenlabeled control chromosome 10-centromeric probe (CEP10; Vysis) (chromosome 10 exhibited few CNAs in the aCGH data). Slides were imaged using a fluorescence microscope with Applied Imaging CytoVision 3.0 software. Red (Chr13q) and green (chr10cen) FISH signals were counted for at least 20 cells per case, and chromosome 13 gain was defined by a red/green ratio >1.5. For IHC, we used a mouse monoclonal antibody directed against CDX2 (Biogenex) or β-catenin (Cell Marque). CDX2 staining was scored from 0 (no nuclear staining) to 3, indicating an increasing extent of nuclear staining. β-Catenin staining was scored as membranous only (1), membranous and cytoplasmic (2), or nuclear (3-6, indicating <5%, 5-10%, or >50% of tumor cell nuclei staining positive, respectively).
shRNA and cDNA Transductions. shRNA constructs in pLKO.1 vectors (The RNAi Consortium) were packaged into lentiviral particles, and target cell lines were transduced and cultured under puromycin selection. Knockdown was confirmed by Western blot analysis. All functional experiments were performed with transduced cells that had undergone fewer than three passages after puromycin selection (to minimize any selective pressure to revert knockdown). Lentiviral expression vectors pLOC-RFP and pLOC-CDX2 were obtained from Open Biosystems and were transduced as above.
Functional Studies. Cell proliferation was quantified by colorimetry based on the metabolic cleavage of the tetrazolium salt WST-1 in viable cells (Roche). Apoptosis was assayed by annexin V staining, quantified by flow cytometry using the Vybrant Apoptosis Assay kit (Invitrogen). Cell-cycle distribution was quantified by flow cytometry using the BrdU-FITC Flow kit (BD Biosciences). For anchorage-independent (soft agar colony) growth, cells were plated in a layer of 0.18% (wt/vol) agarose on top of a layer of 0.36% (wt/vol) agarose. For colony growth on plastic (liquid medium colony growth), cells were plated sparsely in six-well plates. Colonies were stained after 2-3 wk with neutral red (soft agar) or Giemsa (plastic) and were counted using ImageJ software (National Institutes of Health). Loss of contact inhibition was assayed by transduction of NIH 3T3 cells and counting visible foci 3 wk later. For β-catenin/TCF reporter assays, cells were transfected with either TOPflash or FOPflash firefly luciferase reporter constructs, with a Renilla luciferase reporter construct (pRL-TK; Promega) serving as an internal transfection control. Firefly and Renilla luciferase activities were measured using the DualLuciferase Reporter assay system (Promega), and the ratio was reported. All the above assays were performed as biological triplicates, and average values (±1 SD) are reported. All experimental results were reproduced at least once.
